Category Archives: Maine Stem Cells

Hematopoietic stem cell transplantation, or HSCT, is not approved to treat multiple sclerosis in the U.S.

BROWNFIELD, Maine It's a disease that affects 2.3 million people around the world and about one million people in the U.S.

Multiple sclerosisimpacts the brain and central nervous system, causing a number of symptoms that can include vision loss, pain, fatigue, numbness, and neurological problems.

A mom from Brownfield is among a growing number of MS patients heading south of the border to undergo hematopoietic stem cell transplantation, known as HSCT. Last November, Anna Mosca was running a successful dog grooming business out of her home when suddenly her left hand went numb.

"It spread to four fingertips, and it started moving down my hand and moved up my arm. There is something really wrong," Mosca said.

Two trips to the ER still didn't clear up why her symptoms were getting worse. Finally, an MRI and a spinal tap revealedRelapsing-Remitting Multiple sclerosis, a type of MS where symptoms get worse, followed by some improvements. The disease uses your immune system to attack the brain and central nervous system.

Mosca had to close her business. She began walking with a cane.

There is no cure for MS, but the mother of two began taking medications that slow the degenerative disease.

"So they don't stop it. Instead of being in a wheelchair in five years, maybe in 10 years," Mosca explained.

Through a support group, she learned about the hematopoietic stem cell transplant.

According to the National Multiple Sclerosis Society, the treatment involves wiping out the patient's immune system with chemotherapy and rebooting it with the patient's own stem cells so it stops attacking the central nervous system.

The treatment is only available in the U.S. for patients in clinical trials, but Mosca was not considered a candidate. The treatment is also performed in other countries, including Russia and Mexico.

In November, Mosca plans to travel to Puebla, Mexico to undergo HSCT treatment atClinica Ruiz. The clinic has two centers, which have treated more than 1,400 patients with MS and autoimmune disorders. Nearly half are from the U.S.

Dr. Guillermo Ruiz-Arguelles is a hematologist who has trained at the Mayo Clinic. Ruiz-Arguelles, who goes by Dr. Ruiz, says patients stay for 28 days and are sent home with antibiotics and antivirals to help rebuild their immune systems. He says out of five years of following patient outcomes, 80 percent of patients have a positive response to the treatment.

"Forty percent of patients do see a halt to the progression of the disease, and 40 percent do improve their neurological condition," Dr. Ruiz explained.

HSCT costs $54,000 dollars, not including travel expenses. AGoFundMe is set up to help cover Anna's expenses. Other donations are also coming in from the Brownfield community, other parts of western Maine, and New Hampshire.

Thirty-seven thousand dollars has been raised so far. The possibility of putting MS into remission is bringing new hope to Mosca and her family.

"Hopeful urgency where we can potentially see this go away permanently," Anna's husband, Jason Wood, said.

"I want to be able to be a mom to the kids, I want to be a wife," Mosca added.

More NEWS CENTER Maine stories

Read the original post:
Mainer with MS to go to Mexico for stem cell transplantation ...

Jul. 8Nine Maine health care workers who sued Gov. Janet Mills and others over the state's COVID-19 vaccine mandate for health workers now have until Monday to reveal their names.

The Court of Appeals for the First Circuit in Boston on Thursday denied a motion by the workers to remain anonymous and gave them until Friday to comply with the order by filing an amended complaint with their names. But on Friday the plaintiffs were granted an extension of one business day until Monday, July 11 to file the amended complaint.

Attorneys for Liberty Counsel, a conservative, religious law firm in Florida that represents the health care workers, said in a court filing Friday that the one-day extension is needed to give lawyers time to speak with each plaintiff about whether they want to proceed with the disclosure of their identities in an amended complaint.

The defendants and media intervenors in the case, which included the Portland Press Herald, consented to the one-day extension.

The plaintiffs informed attorneys for media intervenors in the case that they will not file further appeals in the case.

The plaintiffs filed their complaint in federal court last August, before the COVID-19 vaccine mandate for health care workers at designated Maine care facilities went into effect on Oct. 20, 2021. They argued that it was their religious right to refuse the vaccine over their belief that fetal stem cells from abortions are used to develop the vaccines.

Maine's mandate does not allow for religious exemptions.

Jeanne Lambrew, commissioner for the Maine Department of Health and Human Services, and Nirav Shah, director of the Maine Center for Disease Control and Prevention, were named as defendants in the lawsuit along with the governor and several health care agencies.

The lawsuit prompted several Maine newspapers to intervene in an effort to force the plaintiffs to be identified. The Portland Press Herald, Kennebec Journal, Morning Sentinel and Sun Journal filed a motion in November 2021 challenging the group's right to file the complaint anonymously. The newspapers argued that the plaintiffs "alleged fear of harm no longer outweighs the public's interest in open legal proceedings," according to court documents.

Story continues

U.S. District Court Judge Jon D. Levy ruled May 31 that the plaintiffs cannot remain anonymous and ordered them to file an amended complaint with their names by June 7. Levy said in his ruling that "plaintiffs' religious beliefs and their resulting medical decisions not to be vaccinated against COVID-19, whether considered separately or together, do not present privacy interests so substantial as to support pseudonymous proceedings. In the final analysis, however, there is a near-total absence of proof that their expressed fears are objectively reasonable."

The plaintiffs appealed the June 7 deadline and were granted until July 8 to comply with his decision, which the appellate court judges upheld Thursday. They wrote in their ruling that the plaintiffs "have not established a threat of irreparable harm."

"The public interest and the media intervenors' interests weigh in favor of denying the stay due to the presumption of public access," the justices wrote.

More:
Maine health care workers have until Monday to reveal names in lawsuit over vaccine mandate - Yahoo News

Linda Coan O'Kresik | BDN

Linda Coan O'Kresik | BDN

A teddy bear is seen in a window in a Hampden neighborhood.

Today is Tuesday. There have now been 1,023 confirmed cases of coronavirus infection in all of Maines counties, according to the Maine Center for Disease Control and Prevention.

Health officials on Monday confirmed the death of a man in his 70s from Kennebec County, bringing the statewide death toll to 51.

So far, 161 Mainers have been hospitalized at some point with COVID-19, the illness caused by the coronavirus, while another 549 people have fully recovered from the coronavirus, meaning there are 423 active cases in the state. Thats down from 433 on Sunday.

Heres the latest on the coronavirus and its impact in Maine.

The Maine CDC will provide an update on the coronavirus at 3 p.m. The BDN will livestream the briefing.

Democratic Gov. Janet Mills on Monday suggested at Mondays coronavirus briefing that she may loosen restrictions on businesses when her stay-at-home order expires on April 30. Mills told reporters she was likely to extend parts of a stay-at-home order. She signaled a shift by saying some restrictions might be lifted gradually based on whether workplaces can conduct business safely and not whether businesses are considered essential, saying she would announce a plan for extending the order on Tuesday.

Maine is now the last state in New England to not release data on coronavirus cases by city and town. Vermont started releasing ranges of cases Monday. The information does not specify which towns may have 5 or fewer cases. New Hampshire takes a similar tactic, but delineates towns that do not have any reported cases. Rhode Island reports the exact number of cases per municipality, as do Massachusetts and Connecticut. The Maine CDC has declined to release similar information, citing privacy concerns. It estimated it could take up to six months to compile that data in response to a Bangor Daily News Freedom of Access Act request last week.

Just four days after Maine confirmed its first case of the coronavirus, Seren Bruce received a different diagnosis that would nevertheless be shaped by the pandemic. On March 16, a doctor at Northern Light Cancer Care in Brewer who had reviewed Bruces bloodwork diagnosed her with non-Hodgkins lymphoma, a type of cancer that grows on the white blood cells. Bruces diagnosis has come at a particularly fraught time for cancer patients, who often have weakened immune systems as a result of their treatments or cancers, and who may be more likely to become seriously ill from the coronavirus. Now, hospitals have delayed all sorts of non-emergency services to preserve their resources and to prevent the virus from spreading among vulnerable patients, leading to delays in some care for cancer patients.

For more than a month now, visitors, including residents family members, have been barred from entering The Commons at Tall Pines in Belfast in hopes that the virus would not take root there. But the virus, stealthy and deadly, found its way in.

Calls placed to the Northern New England Poison Center from peoples homes have increased, according to Karen Simone, a toxicologist who runs the center at Maine Medical Center in Portland, but they do not appear to be a result of President Donald Trumps suggestion Thursday that ingesting certain household cleaners can keep people from getting the disease. Rather the increase seems to stem in part from more intense home cleaning efforts aimed at preventing the spread of the coronavirus and the occasional mishaps that result.

Bowdoin College in Brunswick is facing down a loss of more than $8 million from financial aid to assist low-income students with travel and other coronavirus-related costs and room-and-board refunds after the college opted to not have students return after spring break, making it one of the first Maine universities to close its campus in response to the coronavirus outbreak. Meanwhile, Bates College in Lewiston has already taken a financial hit of up to $2 million because of the coronavirus and the colleges president, Clayton Spencer, anticipates worse to come.

The Maine CDCs headquarters reopened Monday after a coronavirus exposure briefly shuttered the headquarters of the agency responsible for leading the state response to the pandemic.

The eagerly anticipated second round of federal stimulus loans aimed at helping small businesses pay employees during the coronavirus outbreak rolled out on Monday, when the system processing loans almost immediately came to a halt before it began working again sluggishly several hours later.

The billions of dollars in coronavirus relief targeted at small businesses may not prevent many of them from ending up in bankruptcy court. Business filings under Chapter 11 of the federal bankruptcy law rose sharply in March, and attorneys who work with struggling companies are seeing signs that more owners are contemplating the possibility of bankruptcy. Companies forced to close or curtail business due to government attempts to stop the virus spread have mounting debts and uncertain prospects for returning to normal operations. Even those owners receiving emergency loans and grants arent sure that help will be enough.

As of early Tuesday morning, the coronavirus has sickened 988,469 people in all 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and the U.S. Virgin Islands, as well as caused 56,253 deaths, according to Johns Hopkins University of Medicine.

Elsewhere in New England, there have been 3,003 coronavirus deaths in Massachusetts, 2,012 in Connecticut, 233 in Rhode Island, 60 in New Hampshire and 47 in Vermont.

Before her double-lung transplant, Joanne Mellady could barely put on a shirt without losing her breath. Afterward, she barely stopped moving. Mellady, who died of the coronavirus in March, had a bucket list that made her family blush. Mellady, a 67-year-old from New Hampshire, transformed herself from a shy person dependent on oxygen around the clock to a vivacious risk taker willing to try almost anything. Hang gliding, skiing, skateboarding and kayaking were among the thrills she took on.

Follow this link:
April 28 morning update: The latest on the coronavirus and Maine - Bangor Daily News

Democratic Sen. Catherine Cortez Masto said major manufacturers attribute a shortage of masks and gloves for front-line health care workers in part to a lack of government leadership in the supply chain, and shes calling on the president to involve the government in manufacturing the scarce goods.

Cortez Masto made her comments in an interview with The Nevada Independent on Thursday, the day after she voted in favor of a $2.2 trillion emergency aid package aimed at relieving the economic fallout from the bill.

The House is expected to vote Friday on the bill that will include massive amounts of financial aid to large companies and small businesses, as well as hundreds of dollars for most individual Americans. Its the third bill in a series of coronavirus response legislation that included a measure to promote the development of a vaccine, and a bill to provide free COVID-19 testing and paid sick leave.

Read on for highlights of the interview, which also included the senators reaction to speculation that she could be a vice presidential nominee for Joe Biden.

Some large businesses will get help through the stimulus bills to try to keep people on their payroll. Do you think casinos are going to apply for funding and which ones?

I dont know which casinos will apply for the funding or whether they will. But I will say this I have been on the phone with our hospitality industry, from our gamers to the small businesses, to the workers, to organized labor, to restaurant owners.

At the end of the day when it comes to our hospitality industry in Nevada, we are all in this together. Theres 450,000 jobs statewide that this industry employs, 450,000 people. And its from individuals who actually work within the casinos and those who benefit because they have a small business that works with the casinos, from our dry cleaners to our florists to small restaurants.

So the goal here, for me and the whole entire delegation as we work together on this package was to make sure we were taking care of everyone in our industry.

So theres a combination of things within the package that will, at the end of the day, make sure that everybody has some form of liquidity. Cause thats what its about. We are asking people, rightfully so, to shelter in place, to stem the spread of the coronavirus. And because of that, they are potentially losing out on wages, salaries, and health care benefits.

And so the goal here is to make them liquid, put money in their pocket now, help their businesses, those small businesses so that they give them the liquidity they need, so that when this crisis is over, we can open our doors and our economic recovery can kind of spring back that much quicker.

Is there anything you would like to see in any forthcoming legislation coming out of Congress?

Once we get it signed by the president, we get the money out, we will have a better understanding [of] what else we need to do. I am already hearing from our governor, from other governors, from hospitality, from our health care workers that more needs to be done and we are prepared to do that.

So yes, I think there is going to be a fourth package thats going to be necessary, but I think we need to wait to get this one out, get the money out there and see where, where else we can be helpful.

One of the biggest concerns right now is that health care professionals say they dont have the masks and the gloves and the personal protective equipment they need. What can you do as a senator to help address this problem?

What this package does is put more money in there to make sure that our hospitals, not only in our urban, but our rural areas, can keep their doors open and then pay for the personal protective equipment for health care workers, including the testing supplies that are so necessary. So theres money in there for that.

The other thing though that needs to be done, and this is why so many of my colleagues and I have talked and sent letters that it is time for this president to really rely on I know hes invoked the Defense Production Act but he hasnt done anything about it.

He hasnt set it in motion. My concern is there is no one at the national level that is managing the supply and demand of this medical equipment that we need right now. Our governors competing with other governors, on the private market for this equipment. And we need to now manage this at a national level to make sure that the supplies are getting to the states and those local communities and to the hospitals where it is needed.

Jacky Rosen and I were on two conference calls. We wanted to reach out to the manufacturers to find out what were the barriers, whats going on here. So we had separate conference calls, one with Cardinal Health and the other with Medline, who produces a lot of these supplies.

And the one thing that we came away from is theyre getting misinformation. Theyre hearing at the federal level from Health and Human Services and FEMA. Theyre hearing different things and nobody is coordinating one area one person taking control and command to coordinate with everyone. And so that is part of the problem.

What I am hearing from these manufacturers that are producing some of these is they want somebody at the federal level to take control to start managing all of the supplies because that is why we are seeing, unfortunately, price gouging going on.

What would be the next step to have someone in charge of this manufacturing situation?

The president needs to say, as he invoked the Defense Production Act, now he needs to set it in motion and he needs to have one agency, whether its HHS, FEMA, whoever it is, take control of not only that supply and demand of the, this medical equipment nationally but the production of it, to understand what those barriers are cause some of the barriers are.

Some of the products or the chemicals we need are not even in the United States. Theyre in another country. We know the test kits alone need a reagent and were low on that reagent. Well, some of that reagent comes from Maine, but some of it comes from out of the country. And so we need somebody at the federal level that is managing all of that and taking control.

Sen. Harry Reid has asked Joe Biden if he could have you as his running mate. Would you consider being a potential running mate for Joe Biden?

I am so honored to have my name even out there and thought of in that way. But I will tell you right now, I am focused on my job here in the United States Senate. I am honored every single day that I get to work on behalf of the state that I was born and raised in and all the people and businesses that live there.

And really, my focus now is just getting us through this crisis and doing what I can at a federal level to make sure that we have the resources we need in our state and individuals have the health care that they need.

What is your office doing to try to meet the needs of Nevadans without health insurance, including undocumented people?

What I want people to know, first of all, is if they have any questions about anything thats going on, whatever their needs are, to reach out to my office. We have case workers that are bilingual, speak Spanish. We are here to help them and work, get them the resources they need or help them through this process.

I will say in this particular package that weve passed, theres a couple of things I want people to know. The package includes $1.3 billion to cover testing costs at community health clinics. And I know those community health clinics in our state serve patients regardless of their immigration status.

So I would tell anyone that if they feel the symptoms or they didnt feel well because, and theyre having the symptoms of coronavirus, to go to one of those community health clinics. The other thing they need to know is if they seek that assistance, it will not be counted against them as part of their public charge analysis.

We were able to, to work with the federal government to make sure that anybody seeking attention and medical needs or assistance because of this virus, will, this will not be used against them. We want people to come forward and we want them to get the healthcare that they need.

A couple of other things. Theres unemployment benefits that we expanded in this package. Anyone who has a valid work authorization during both the time that they were employed and the time they were unemployed can apply for these benefits. This includes both DACA and TPS beneficiaries.

The only thing that, I think, this bill has a shortcoming in is on the direct payments that go to individuals and families. Only those with valid Social Security numbers qualify for the one time payment.

We published an article about fears among ICE detainees that they could be vulnerable to catching coronavirus in these detention centers. What can be done about this situation?

So what we have done at the federal level is I was part of a letter along with my colleagues that we sent it to ICE demanding what type of action they are going to take to prevent the spread of the coronavirus in their detention facilities. And Im waiting. Many of us are waiting for that response.

Theres other ways that we can release them into the community without having to detain them.

We have so many new technologies now and things that we can do to work with them and their attorneys to help them out.

And I think thats what we should be focused on. You know, many, many folks in ICE right now, theyre not violent criminals. And what Im seeing and hearing is that some of them are even put in cells with violent criminals. Theyre not. And so we have to, if were really gonna stem the spread of this virus, then we have to focus on every population.

The Supreme Court is expected to rule in June on the legality of DACA. What can be done for our DACA population that was already concerned about this, and that stress has been compounded by the coronavirus?

I think at this point in time, my concern is that this administration, even though he has said that if he wins this litigation and I mean this president, as the one who brought this litigation forward if he wins, hes not gonna do anything to harm our Dreamers.

I dont trust him and I dont think anybody should in this case, because weve seen what hes done with our immigrant populations. pitting them against one another, calling them horrific names and instilling fear in our community. What it requires us right now is to continue to fight to protect this community.

But at the same time, Ill be honest with you, it means that we have to all come out and vote and elect individuals who are going to stand up for everyone in this country. We are a nation of immigrants Most of us come from immigrants whove come to this country for a better life, and I think that is the beauty of the United States, and thats worth fighting for.

View post:
Indy Q&A: Cortez Masto wants government to take greater charge of mask, glove supply chain - The Nevada Independent

While a college student in Worcester, Brian Clark, of Ashfield remembers when he read for the first time about the American chestnut, once known as Americas most iconic tree, which by then had become decimated by blight from Mississippi to Maine.

Back in Ashfield, his father, Malcolm, told him, Oh yeah, I remember going out on Ridge Hill when I was a kid with my mother to collect chestnuts. Malcolm Clark remembered later trying to get a chestnut sprout from a neighbors farm to grow, without success.

The fast-growing American chestnut, which could reach 100 feet tall and 10 feet in diameter, had light, straight-grained wood that was popular for furniture and timber, shingles and flooring. The wood had also been used by native Americans for dugout canoes, its leaves and bark had medicinal properties, and its nuts were a nutritious food supply for humans and wildlife.

Clark, who is now vice president of the American Chestnut Foundations Massachusetts-Rhode Island Chapter, examined a grove of about 3,000 chestnut trees recently at Smith CollegesAda and Archibald MacLeish Field Station in West Whately some of them the smaller, multi-stem Chinese chestnut, which is blight resistant. Most, though, were American chestnut saplings, planted from seeds collected around the region by the roughly 300-member foundation.

Now in its eighth year, this one-acre orchard is one of three test plots of American chestnuts in Franklin County there are also two research groves in Conway and Hawley, including a 150-acre plot in Conway State Forest that are part of an effort by conservationists experimenting with ways to cross-breed in resistance, in order to restore through hybridization this functionally extinct grand tree to American forests.

The method, developed in the late 1970s by ACF founder Charles Burnham, breeds blight resistance into the American chestnut by backcrossing the best characteristics of American and Chinese varieties. In theory, the hybrid would blend 94 percent American and 6 percent Chinese genes.

Paul Wetzel, who oversees the Whately test orchard as a staff ecologist for Smith Colleges Center for Environmental and Ecological Design and Sustainability, points to the rusty-colored wound of the blight on a sample tree just above where it was inoculated as part of an ongoing experiment to see which of the Chinese-American hybrids are most blight resistant. The blight girdles the stem, locking the trees cells above to prevent water from being carried up. Below the canker, the chestnuts roots and stem can live on and send out shoots that may reach 15 feet or more before succumbing to blight again. Millions of American chestnuts therefore survive, but very few reach the stage where they are able to flower and reproduce.

The Whately breeding grove boasts hybrids from three rows of each of 20 different genetic lines from Chinese chestnuts, combined with seeds from American chestnuts from around Massachusetts and Rhode Island in an attempt to bring about as much diversity as possible.

With 16 ACF chapters, its hoped that maximum genetic diversity can produce trees that fight off blight as well as other pathogens or predators to make a comeback over time.

Even though its all the same species, there may have been some local adaptations to the environmental conditions across such a big region, said Wetzel. The idea of having local chapters is to take local trees and cross them with the Chinese trees, so if there is some local adaptation that gets passed into the genetics, it will still be there. Its estimated there were 4 billion American Chestnuts in North America before the blight, and if all of a sudden it funnels down to 500 or 1,000, theres a huge genetic bottleneck. If you just took a tree thats growing in Maine and started propagating it, youd essentially have a monoculture across the whole area.

For that reason, he said, its important to be mindful of assuring theres a diverse genetic pool, regardless of whatever species thats being reintroduced.

With the threat of climate change, there are also concerns that a different pathogen, which rots the trees roots but has only been a problem in the South where ground freezing doesnt occur, may begin moving northward as well.

Efforts to bring back the American chestnut stir not only the imagination, says Wetzel, but also cultural memories about a tree that was such a core part of eastern forests.

The chestnut was a very culturally important tree to eastern North America. It had the most economic value of any species of tree. It grows fast, it grows in many different areas, except for wet areas, and the wood is strong, its easy to work and its rot-resistant. It produces great nuts, theyre very high-protein and produced a lot of food for wildlife. Theres this whole cultural background. People talked about roasting chestnuts and buying it off the streets in big cities. It was the original fast food.

At least nine genes, according to Wetzel, are responsible for the resistance of the smaller, orchard-size Chinese chestnut trees, and its been thought that hybrids with their American cousins. ...With 45 percent of American chestnut to advance its more familiar characteristics, may be whats needed to bring back the tree that was once loved.

As the chestnut advocates try to accelerate the regeneration that would occur naturally, Wetzel says, We thought we were pretty close. We thought we were creating seeds that are resistant, but then were finding out, if you look at 150 trees, most of them have some blight canker on them, and Ive already cut down the worst ones. The original Burnham program was designed on the assumption that only two to three genes were involved in resistance.

But extensive genetic analysis theyve begun doing in the past few years has shown there are at least nine, so theyre seeing the need to step up the effort, maybe by lowering expectations from a tree thats 94 percent American to allow natural selection to do more of the sorting, or maybe crossing more Chinese varieties that have natural resistance to the blight. There are also efforts to develop a cost-effective way to test younger saplings for resistance, as well as tests of a transgenic approach to hybridize an American chestnut seed with the same kind of natural blight resistance that occurs in wheat and other grains.

The work is important, and much of it is done primarily by volunteers. Funding comes primarily from ACF members.

Using seeds available from the foundation, Clark has an American chestnut growing in front of his house that he guesses is more than 35 feet tall, part of a grove that hes hoping will continue to flourish. But getting the trees to make a real comeback on a wider scale, he and Wetzel say, will take time, more research and plenty of patience.

Recently retired, Richie Davis was a writer and editor for more than 40 years at the Greenfield Recorder. He blogs at richiedavis.net.

See the original post:
Saving theAmerican chestnut - The Recorder

I recently had an experience that highlights, for me, some of what is wrong with our medical insurance system.

I love playing tennis, but my knees have been deteriorating. The cushioning material is wearing away, and there is arthritis. The increasing pain and swelling I was experiencing led me to consider knee replacement surgery, or the end of my tennis career. Neither choice was appealing.

My naturopathic doctor suggested I consider PRP therapy. Platelet-rich plasma treatment has been growing in popularity because it often provides an alternative to knee- and hip-replacement surgery. It can also help tennis tendinitis and rotator cuff injuries. Professional athletes, including Tiger Woods, use PRP therapy. Despite its successful track record, it is not covered by insurance, Medicare or otherwise.

PRP therapy involves removing a small amount of ones blood and separating out its components in a centrifuge. The concentrate is then injected into the area that needs help. The platelet-rich blood attracts stem cells, the bodys repairmen, to the area to rebuild tissue, muscles and tendons.

I love this concept because it uses the bodys own healing ability to rebuild worn-out parts. As a lifelong proponent of homeopathy and other natural healing modalities, I decided to give PRP a try. On Sept. 10, I drove to the office of Dr. John Herzog in Falmouth, Maine, to check it out, despite the fact that Medicare would not cover the cost.

Dr. Herzog is an osteopathic orthopedic surgeon who has performed thousands of surgeries to replace knees and hips over his 30-year career. In 2009 he decided to stop doing surgery and focus on PRP, after finding how much it helped his own knee condition. He has treated more than 3,000 patients since then, with an 80% success rate.

After a basic physical exam to see how well my knees flexed, we looked at them with ultrasound. It was fascinating to watch as Dr. Herzog explained the state of each knee cavity. Fortunately, I was not in a complete bone-on-bone condition; both knees were good candidates for PRP treatment.

I initially thought I would test the treatment on one knee, but opted to have both done. The cost was $600 for one knee, $1,000 for both. Despite paying for this out-of-pocket, it seemed a reasonable cost given the much more expensive alternatives. Knee and hip replacements average $30,000.

Dr. Herzog drew a cup of blood from my arm, put it in a centrifuge and injected the platelet-rich concentrate into both knees. I was out of the office on my way home in a little over an hour. I was told results were normally felt within 4 to 6 weeks, and could last up to a year or more. Every person responds differently, some return for tune-ups after a year.

The following day both knees were quite sore and swollen as blood and oxygen rushed to the area. The next day the swelling began to subside, and five days after the treatment I played tennis. Now, some two months later, the results have been remarkable. Both knees are stronger. Recovery after tennis is greatly reduced. I stopped wearing knee braces, and my movement on the court is now the best its been in years. Im considering playing three times a week instead of two. I feel a little bit like Forrest Gump!

Given the significant success rate of this treatment, the low cost, low risk and absence of side effects, why is it not covered by medical insurance? When I posed this question to a spokesperson at Concord Orthopedics, where one doctor now offers the treatment, their guess was the lack of clinical data on PRP therapy. Its clear this therapy is rapidly gaining in popularity because it is effective and inexpensive.

Dartmouth-Hitchcock offers PRP treatments. Vermont Regenerative Medicine, located in Burlington, recently ran a series of full-page ads in the Monitor advertising their services.

You would think insurance companies and the medical establishment would jump on embracing such benign treatment. I was able to afford the $1,000 fee to have both knees treated, but how about all the people who cannot?

For many years, acupuncture and chiropractic care were not covered by medical insurance. Now they are. Similar to PRP therapy, they are effective, non-invasive and low cost. All therapies that employ our bodys healing ability to recover from injury should be put at the top of the list of treatments covered by insurance. Especially when they offer a true alternative option to more expensive and invasive surgery.

(Sol Solomon lives in Sutton.)

Go here to see the original:
My Turn: The malaise of medical care - Concord Monitor

There have been 145 orthopedic surgeon moves in 2019 so far.

Eric Smith, MD, joined New England Baptist Hospital in Boston as chief of arthroplasty.

Cody (Wyo.) Regional Health added Christopher Rice, MD, to its staff.

Piedmont Rockdale Orthopedics in Conyers, Ga., welcomed Stephenson Ikpe, MD.

Abby Maxwell, MD, and Charles May, MD, joined Western Carolina Orthopaedic Specialists at Haywood Regional Medical Center in Clyde, N.C. Gerald King, MD, is rejoining the practice in November after retiring earlier this year.

Scott Steinmann, MD, was named orthopedic department chair at the University of Tennessee Health Science Center College of Medicine in Chattanooga.

Orthopedic surgeon Jonathan Godin, MD, joined Vail, Colo.-based The Steadman Clinic, where he completed his fellowship.

Bret Smith, DO, joined Mercy Orthopedic Associates' Foot and Ankle Center in Durango, Colo.

Rock Springs, Wyo.-based Memorial Hospital of Sweetwater County welcomed Tony Pedri, MD.

White Plains (N.Y.) Hospital welcomed Isaac Livshetz, MD.

Odessa (Texas) Regional Medical Center added orthopedic surgeons Luv Singh, MD, and Saravanaraja Muthusamy, MD.

Anuj Netto, MD, joined Phoenix-based The Orthopedic Clinic Association.

OrthoCarolina added seven orthopedic surgeons: Malick Bachabi, MD, Michael "Canaan" Prater, DO, Brian Opalacz, DO, Jesse Otero, MD, PhD, Bryan Saltzman, MD, Andrea Staneata, MD, and Adam Wegner, MD, PhD.

Tampa-based Florida Orthopaedic Institute welcomed Evan Loewy, MD.

Patricia Fox, MD, and Rabun Fox, MD, a husband and wife orthopedic surgeon team, joined Anchorage (Alaska) Fracture & Orthopedic Clinic.

Raj Rangarajan, MD, joined Institute of Movement and Orthopedics at Beaver Dam (Wis.) Community Hospital and Marshfield (Wis.) Clinic Health System.

Travis Littleton, MD, joined OrthoAtlanta.

Orthopedic surgeons Heeren Makanji, MD, and Kevin Choo, MD, joined Orthopaedic and Neurosurgery Specialists in Greenwich, Conn.

Four orthopedic surgeons joined Richmond-based OrthoVirginia: Elliott Kim, MD, Nathan Coleman, MD, William Petersen, MD, and Jonathan Bernard, MD.

Lawton, Okla.-based Southwestern Medical Center welcomed Thomas Joseph, MD.

Direct Orthopedic Care, with several locations in Texas as well as Oklahoma City and California, welcomed Kyle McGivern, DO.

Jessica Brozek, MD, joined Newton (Kan.) Orthopedics & Sports Medicine.

Jason Boyd, MD, joined Salem (Ohio) Regional Medical Center.

Central Michigan Orthopaedics in Union Charter Township welcomed Ryan Lilly, MD.

Ryan Hubbard, MD, a nonsurgical orthopedic clinician, joined Anderson Orthopaedic in Alexandria, Va.

Greenville, S.C.-based Carolina Orthopaedics and Neurosurgery welcomed Travis Patterson, MD.

Bend, Ore.-based The Center Orthopedic & Neurosurgical Care welcomed Christopher Healy, DO.

Dustin Price, MD, joined the orthopedic team at Watauga Orthopaedics in Johnson City, Tenn.

Edward Schleyer, MD, joined Coastal Orthopedic Associates in Beverly, Mass.

Chicago-based Midwest Orthopaedics at Rush welcomed Jorge Chahla, MD, PhD.

Jarrad Barber, MD, joined Rome, Ga.-based Harbin Clinic Orthopedics.

Christina Kane, MD, and Ashley Miller, MD, joined Pittsfield, Mass.-based Berkshire Orthopaedic Associates.

Franklin, Tenn.-based AdvancedHealth welcomed Heather Melton, MD.

Orthopaedic Specialists in Davenport, Iowa, welcomed Kristyn Darmafall, MD, and Megan Crosmer, MD, who will join in mid-September and early October.

Domenic Scalamogna, MD, joined OrthoAtlanta and will practice at its locations in Fayetteville, Newman and Peachtree City, Ga.

MidMichigan Health in Midland welcomed James Lewis, DO.

Holden Heitner, MD, joined Watertown, N.Y.-based Samaritan Medical Center.

WVU Medicine Orthopedics-Spring Mills in Martinsburg, W.Va., welcomed Dwight Kemp, DO, who previously spent 25 years in private practice.

Farmington, Maine-based Franklin Memorial Hospital welcomed Raymond White, MD, and F. Lincoln Avery, MD, to its orthopedic medical staff. Dr. White specializes in orthopedic trauma and fracture care and Dr. Avery focuses on orthopedic and sports-related injuries.

Leslie Vidal, MD, joined her husband Armando Vidal, MD, and the surgical team at Vail, Colo.-based The Steadman Clinic on Aug 1.

Matthew Gnirke, MD, will join Vail (Colo.) Summit Orthopaedics and Neurosurgery in August. Dr. Gnirke specializes in interventional sports and spine medicine and treats a range of musculoskeletal conditions with orthobiologic treatments such as platelet rich plasma and bone marrow aspirate concentrate stem cells.

Gregory C. Mallo, MD, is leaving his position as chief of Port Jefferson, N.Y.-based St. Charles Hospital's shoulder service to join Merrick, N.Y.-based Orlin & Cohen Orthopedic Group.

Mark Cullen, MD, joined the orthopedic surgery team at Wentworth Health Partners Seacoast Orthopedics & Sports Medicine in Somersworth, N.H.

Fall River, Mass.-based Saint Anne's Hospital, part of Dallas, Texas-based Steward Health Care, added four orthopedic surgeons to its medical staff. The four surgeons Jerald Katz, MD, Richard Smith, MD, Glenn Dubler, MD, and Mena Mesiha, MD will practice at Saint Anne's Orthopedics on the PrimaCARE campus in Fall River.

Orthopedic Surgical Practice in Santa Barbara, Calif., added a Bryan Emmerson, MD, to its team. He joined the practice on Aug. 1 and specializes in knee and hip replacement.

Robert LaPrade, MD, left Vail, Colo.-based The Steadman Clinic for Golden Valley, Minn.-based Twin Cities Orthopedics.

Orthopedic surgeon Anto T.A. Fritz, MD, joined Healthpointe, based in Los Angeles.

Lisa Lattanza, MD, left the University of California, San Francisco to become chair of the orthopedics and rehabilitation department at Yale School of Medicine in New Haven, Conn.

Mohamed Mahomed, MD, joined Kansas Joint & Spine Specialists in Wichita.

Logansport (Ind.) Memorial Hospital welcomed Kral Varhan, MD, to the Logansport Memorial Physician Network.

South Side Hospital in Bay Shore, N.Y., promoted Michael Nett, MD, to chair of orthopedics.

William Ross, MD, joined Glasgow-based South Central Kentucky Orthopaedics.

Orthopedic surgeon Matthew Werger, MD, joined Tauton, Mass.-based Morton Hospital and Steward Medical Group in Brockton, Mass.

David Johannesmeyer, MD, an orthopedic surgeon with a subspecialty in sports medicine, joined Lowcountry Orthopaedics and Sports Medicine in Charleston, S.C.

Commonwealth Health Wilkes-Barre General Hospital welcomed orthopedic surgeon Johnny Hernandez-Gonzalez, MD.

Rod Wigle, MD, an orthopedic surgeon in Bend, Ore., retired from practice.

Chris FitzMorris, DO, joined Mount Washington, N.H.-based Memorial Hospital.

Via Christi Hospital in Pittsburg, Kan., welcomed Terry Schwab, MD.

Emporia, Va.-based Southern Virginia Regional Medical Center welcomed Manish Patel, MD.

OrthoCarolina Lincolnton (N.C.) brought on sports medicine specialist Verano Hermida, MD.

The Steadman Clinic in Vail, Colo., welcomed Armando Vidal, MD.

Sanjeev Bhatia, MD, left Mercy Health Cincinnati Sports Medicine & Orthopaedic Center to join Northwestern Medicine Regional Medical Group in Winfield, Ill., and became co-director of Central DuPage Hospital's new Hip and Joint Preservation Center.

Ali Dalal, MD, joined Fresno, Calif.-based Sierra Pacific Orthopedics.

Dover, Del.-based Bayhealth welcomed Justin Connor, MD.

Orthopedic surgeon Glen Rudolph, MD, joined Orthopaedic Associates of Duluth (Minn.).

Portsmouth, N.H.-based Atlantic Orthopaedics & Sports Medicine welcomed Michael Moorwood, MD.

Lew Schon, MD, joined Baltimore-based Mercy Medical Center as director of orthopedic innovation at The Institute for Foot and Ankle Reconstruction.

Brian Buck, DO, joined Phoenix-based The CORE Institute.

Stephen Mitros, MD, retired from his practice at Mitros Orthopaedics in South Bend.

Orthopedic surgeon Glen Rudolph, MD, joined Orthopaedic Associates of Duluth (Minn.).

Oswego (N.Y.) Health welcomed orthopedic surgeons Michael Diaz, MD, who specializes in total joint replacements, and Greg Keller, MD, who focuses on shoulder and elbow repair.

Vincent Waldron, MD, joined Angola, Ind.-based Cameron Orthopedics.

Julia Bulkeley, MD, a pediatric orthopedic surgeon, joined OrthoCarolina Laurinburg (N.C.).

Thornton, Colo.-based North Suburban Medical Center's OrthoOne practice welcomed Darryl Auston, MD.

OrthoNeuro in Columbus, Ohio, welcomed J. Mark Hatheway, MD, and James Cassandra, MD.

Albany, N.Y.-based The Bone & Joint Center added three orthopedic surgeons to their staff: trauma surgeon Ernest Chisena, MD, pediatric orthopedic surgeon Abigail Mantica, MD, and hand and upper extremity surgeon Patrick Marinello, MD.

Virgil Meyer, MD, founder of Little Falls (Minn.) Orthopedics, announced he will retire in July.

Spine surgeon Keith Osborn, MD, joined Cummings, Ga.-based Northside Hospital Orthopaedic Institute.

Norwalk, Ohio-based Fisher-Titus Health added Tim Moore, MD, to its spine surgery staff.

Doug Beacham III, DO, joined The Spine Clinic of Oklahoma City.

Daniel White, MD, of Casper (Wyo.) Orthopedics now sees patients at Johnson County (Wyo.) Memorial Hospital.

Sports medicine specialist James Chesnutt, MD, joined Rebound Orthopedics & Neurosurgery in Vancouver, Wash.

Mark Ghaida, MD, joined Crookston, Minn.-based RiverView Health.

Albany, N.Y.-based The Bone & Joint Center welcomed Ernest Chisena, MD, Abigail Mantica, MD, and Patrick Marinello, MD.

Fatima Hospital in North Providence, R.I., named John Czerwein Jr., MD, chief of orthopedics.

Domenic Esposito, MD, joined Durango, Colo.-based Animas Orthopedic Associates.

Michael Holmoe, MD, joined Avera Orthopedics in Brookings, S.D.

Arthritis Total Joint Specialists in Lawrenceville, Ga., welcomed Robert Wood, MD.

Mark Warner, MD, resigned his post at Sheridan (Mich.) Community Hospital one year after joining.

Hand surgeon Michelle, Moyer, MD, joined Poughkeepsie, N.Y.-based Orthopaedic Associates of Dutchess County.

University of Alabama at Birmingham named Steven Theiss, MD, chairman of the department of orthopedics.

Springfield-based The Orthopedic Center of Illinois welcomed Varun Sharma, MD.

Chad Bender, MD, joined Centralia-based Washington Orthopaedic Center.

Southwestern Vermont Medical Center Orthopedics and Dartmouth-Hitchcock Putnam Physicians, both based in Bennington, Vt., welcomed Michaela Schneiderbauer, MD.

Stanford University School of Medicine in Palo Alto, Calif., named Kevin Shae, MD, the Chambers-Okamura Endowed Professor of Pediatric Orthopaedics.

Michael Veale, MD, joined Cleveland-based Center for Sports Medicine and Orthopaedics.

Bennington-based Southwestern Vermont Medical Center Orthopedics welcomed Ivette Guttmann, MD.

Murfreesboro, Tenn.-based Saint Thomas Rutherford Hospital hired retired orthopedic surgeon Richard Rogers, MD, as interim CMO.

Rifle, Colo.-based Grand River Health welcomed Hugh Brock, MD.

Melbourne, Fla.-based First Choice Medical Group welcomed orthopedic surgeon Allison Wade, MD.

Read more from the original source:
145 orthopedic surgeon moves in 2019 through Q3 - Becker's Orthopedic & Spine

Stem Cell Therapy in Maine Stem Cell Therapy uses stem cells remove from the patients own tissue and have the ability to renew themselves and transform into a variety of different cells. This process replaces dying cells, and regenerates tissues that are too damaged to heal on their own. Concentrated stem cells are injected in to the damaged area and can stimulate the formation of cartilage, tendon, ligaments, bone and fibrous connective tissues, to help the body heal naturally.

Stem Cell Therapy Maine, is the utilization of undeveloped cells to treat or keep a sickness or condition. Bone marrow transplant is the most broadly utilized undifferentiated cell treatment, however a few treatments got from umbilical line blood are likewise being used.

Stem cells live in all of us and they act as the repairmen of the body. However, as we age or get injuries, we sometimes cant get enough of these critical repair cells to the injured area. Stem cell injections Maine, procedures of Stem Cell Representatives help solve this problem by greatly increasing your bodys own natural repair cells and promote healing. This is accomplished by harvesting cells from areas known to be rich in mesenchymal stem cells and then concentrating those cells in a lab before precisely reinjecting them into the damaged area in need of repair.

Pain management

Pain management can be basic or complex, contingent upon the reason for the torment. A case of suffering that is regularly less intricate would be nerve root bothering from a herniated circle with agony transmitting down the leg. This condition can regularly be mitigated with an epidural steroid infusion and active recuperation.

We do stem cell therapy in Maine, USA with the the specialisation of following treatments:

Knee stem cell procedures:The most common treatment for patients looking for an alternative to arthroplasty or knee replacement.

Shoulder Stem Cell Procedures:Those that have a rotator cuff tear, shoulder arthritis, tendonitis, or bursitis, may be a good candidate for stem cell therapy.

Hip Stem Cell Procedures:Surgeries on the hip are normally very traumatic followed by months of pain difficult to deal on a daily basis

In spite of the considerable number of realities specified previously and the quickened information about immature microorganisms treatments; there are just a couple of centers in the United States that are lawfully endorsed up until this point.

We offer latest and newest medical treatment at prestigious healthcare facilities, as well as the opportunity to enjoy of our beautiful State of US Maine, at the same time you improve your quality of life. Contact Us now.

More:
Stem Cell Therapy in Maine Stem cell injection & Pain ...

I had my 25th class reunion this past weekend. Flying all the way back to Maine, having flights delayed then cancelled (thanks American Airlines), and then needing to rent a car to drive 9 hours from Philadelphia to Bangor gave me more grey hairs than I already had. But going to my 25th class reunion, I was already grey and balding. So what?

Months before I was to attend, I was trying a new product out to "lessen the amount of grey" that I was sporting up there. I didn't tell any of my friends or my barber. It was a gradual fade that my roommates and even my workwife did not notice I was doing, but they could tell something was different. It was so good that they were recommending it to their loved ones over the products they were already using.

Was I cheating? Was I going to be lying to my classmates? Would I lose some of my daddy bear status? I was going to continue anyway.

Soon, we all may have a way to be less grey and even fill in some spots.

Dallas doctor finds the root of balding and graying hair and is working on treatment

When the mice went gray and bald, the doctor knew he was onto something.

For more than 10 years, Dr. Lu Le had studied cells and genes, hoping to understand the roots of cancer and further the search for a cure.

Instead, in his lab at UT Southwestern Medical Center, he discovered something unexpected a chemical and biological process that could explain gray hair and bald heads in people.

Science often works this way. A search in one direction leads to an entirely different discovery in another. For Le, baldness and graying werent concerns of his research. And yet, there they were, gray and bald mice inside his lab. - dallasnews.com

Accidental discovery

Accidents are a good thing, no? While focusing on how cancer begins, Le and his discovered the role a protein called KROX20 plays not just in nerve development but in hair color and growth.

The KROX20 protein turns on in skin cells that develop into shafts of hair. These cells then produce a protein called stem cell factor (SCF) that is essential for hair color. When that SCF protein was deleted from mice in KROX20 cells, their hair turned gray and then white. And when the scientists deleted the KROX20 cells, the mice turned bald.

"The mice turned gray and then completely white. That was unexpected," Le said. - dallasnews.com

Whether baldness and loss of hair color is reversible is a long way from being answered.

If doctors could prevent greyness and balding, would you do it?

Would you entertain the idea of growing back your hair or getting rid of the grey?

I stopped coloring my hair a month before the reunion, had all the fake color cut out and didn't think twice about it.

h/t: dallasnews.com

See more here:
Balding & Greying May Soon Be A Thing Of The Past. Get Your ... - Instinct Magazine

Transformation of a new scientific idea into a new oncology-based drug requires atremendous amount of time, effort and investment. The initial, but critical first step in thisprocess is transferring basic oncology research into a clinical application known as atranslational or bench to bedside study. As a postdoctoral fellow who performsprostate cancer research related bench work, I have been asking how long my project might take to reach a patient as a cure rather than just becoming another scientific publication! I realize that for a cancer patient who has been waiting for a new drug treatment to survive, the time length that is required for drug development could actually cost the patient their life. From this point of view, the time length between bench work and a follow-on translational study (also called time lag) is critically important. Clearly the biggest problem is to ask and determine how it could be possible to decrease the time lag and allow potential benefits of a bench work to reach patients more quickly.During my Advanced Studies in Technology Transfer program at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH, I worked to uncover answers for these questions as my Capstone Project.

The calculated time lag typically of 10 years for new oncology treatmentBefore proposing solutions to shorten time lag in oncology drug development, I wanted to better define the time lag between bench work and translational study. For this purpose, I used the Pharmaprojects database (produced by Citeline/Informa PLC), to follow the global clinical drug development from bench to patient and to calculate the time lag for the three most common cancer types: breast, lung and prostate cancer. 97 drugs were examined for time lag calculation for either breast, lung or prostate cancer. The time length between patent priority date and regulatory approval date was calculated for each drug. The average time required to launch a cancer drug was determined to be 11 years, 10 years and 10 years, respectively for breast, lung and prostate cancer.

What are the reasons for time lag?To be able to uncover the reasons for a 10 year long time lag in cancer drug development, the key opinion leaders, including principal investigators, scientists, researchers from the National Cancer Institute (NCI), the National Center for Advancing Translational Sciences (NCATS), Yale University, Massachusetts Institute of Technology (MIT), Queens University School of Medicine, Dentistry and Biomedical Science, Belfast (U.K), and Regeneron Pharmaceuticals were interviewed, to formulate suggestions for helping new drugs reach from bench to bed side more quickly.

During these interviews, the following questions were discussed:

Scientific and Non-Scientific Reasons for Long Time Lag

For cancer patients, the10-year period to translate a new drug into clinical application is unfortunately more than a life time of delay. After interviews with many researchers, the reasons for a 10 year long time lag could be divided into two categories, scientific and non-scientific reasons. Problems in reproducible data generation, inappropriate use of in vitro/vivo models, and variation in human sample collection are classified as important scientific reasons. On the other hand, poor collaboration among industry and academia, problems in intellectual property (IP) sharing, ineffective public-private partnership due to lack of sharing of research tools are considered as non-scientific reasons.

Future Direction in Oncology-Based Drug Development:Collaboration, Collaboration and Collaboration!

One of the most common recommendations from all researchers whom I interviewed was the importance of collaboration. Most of the researchers think that collaboration should be considered as an inevitable requirement for all scientists to shorten the time lag, because no one can do all by himself/herself. This would encourage the application and use of differing expertise and points of views to support a steadier and more effective overall oncology research program.

Synergy between Academia and Industry

Researchers from both academia and industry also highlighted the importance of academia and industry partnership. Academic researchers have deep scientific knowledge, however they have been facing funding problems to pursue their researchand utilize this basic knowledge. On the other hand, pharmaceutical companies generally have funding and applied skills, but they are often dependent on academiaand small biotech companies for fundamental knowledge and novel discoveries. It isreally a relay race against time for scientists from both academia and companies needto complete together in order to benefit oncology patient care. Therefore establishing astronger and living connections between academia and pharmaceutical companies cancreate a shortcut and synergy to make to the journey from bench side to bedsidequicker than ever before.

Repurposing of FDA Approved Drugs for Oncology Applications

For one of the interviews for this article, a principal investigator from a major universitysaid that the time lag in bringing his research to market is only 2-3 years, because hislaboratory studies FDA-approved drugs for different indications. Using FDA-approved drugs for other indications, or repurposing the drug, would dramatically reduce time lagand overall cost. The most exciting part of successfully repurposing drugs, of course, is that development of a drug into a new treatment for a patients benefit will be quicker.

About the AuthorBerna Uygur is Postdoctoral Intramural Research Training Award Fellow at NICHDwhere she has been researching the role of cell fusion mediated cancer stem cell regeneration and drugresistancein prostate cancer microenvironment and she has been also researching extracellularvesiclesmediated communication between prostate cancer cells. Prior to joining theNICHD,Berna received her PhD in Biochemistry and Molecular Biology from UniversityofMaine, USA, where she studied Regulatory Role of Slug Transcriptional Factor inProstateCancer. She received her Master of Science degree in Applied MedicalScience from Universityof Southern Maine, USA, where she studied Toxicology ofSilver Nanoparticles in DifferentOrigins of Human Cells. She received both her firstMaster of Science degree and Bachelor Science degree in Textile ChemistryEngineering from Ege University, Turkey. Berna isinterested in translational scienceand technology transfer in biomedical research. Sheadvanced her interest intechnology transfer by completing the Advanced Studies inTechnology Transferprogram at the Foundation for Advanced Education in the Sciences (FAES) GraduateSchool at NIH. She has been pursuing her interest in translational science byattendingNIH-Duke University Clinical Research Training Program at NIH.

Like Loading...

Related

Read the original:
A Guide to Time Lag and Time Lag Shortening Strategies in Oncology-Based Drug Development - Biotech Blog (blog)